Bivalirudin Trifluoroacetate | CAS 128270-60-0 | Direct Thrombin Inhibitor (Research Use Only) | Knowlux

Product Description

Bivalirudin Trifluoroacetate, CAS 128270-60-0, is a synthetic 20-amino-acid peptide supplied by Knowlux for laboratory research use. It is a direct thrombin inhibitor and a hirudin analogue, formulated as the trifluoroacetate salt to improve solubility and stability. The molecular formula is C98H138N24O33 and the molecular weight is approximately 2180.3 g/mol (trifluoroacetate salt form). Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Form clarification: CAS 128270-60-0 is consistently recorded as bivalirudin trifluoroacetate across ChemicalBook, GuideChem and supplier COAs. The free peptide base has a slightly different mass; Knowlux declares the counter-ion (trifluoroacetate) and assay basis on each COA. The sequence is D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH.

Product Parameters

Product Details

1. Overview

Bivalirudin is a synthetic 20-amino-acid peptide that acts as a direct, reversible inhibitor of thrombin. It was designed as a hirudin analogue and received initial FDA approval in 2000 for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI). Unlike heparin, bivalirudin does not require antithrombin as a cofactor and is capable of inhibiting both circulating (soluble) and clot-bound thrombin. The trifluoroacetate salt form is the pharmaceutically relevant form used in the approved injectable product, and Knowlux supplies this salt for laboratory and analytical use.

2. Mechanism of Action

Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine protease that cleaves fibrinogen to fibrin and activates factors V, VIII, and XIII, thereby stabilizing the thrombus. Bivalirudin binding is reversible: thrombin slowly cleaves the bivalirudin Arg3-Pro4 bond, resulting in recovery of thrombin active site functions. In in vitro studies, bivalirudin inhibited both soluble and clot-bound thrombin, was not neutralized by platelet release products, and prolonged aPTT, thrombin time, and prothrombin time in a concentration-dependent manner.

3. Quality Control

4. Applications

• Reference standard for direct thrombin inhibitor analytical methods

• Thrombin binding and inhibition assay development

• Coagulation cascade research models (aPTT, TT, PT assays)

• Formulation development for injectable anticoagulant peptides

• LC-MS, immunoassay and bioassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Bivalirudin is approved as a prescription medicine (Angiomax and generics) in many jurisdictions as an anticoagulant for PCI; that regulatory status is specific to the approved pharmaceutical products and does not extend to this research-grade supply as sold by Knowlux. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.